Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.
Also called NCT05243199
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 330 participants
- Sponsor
- Registry
-
NCT05243199
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05243199. Randomized; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2023-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
- Condition
- CKD5 Stage Dialysis
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril/Valsartan
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- Ruijin Hospital
Record details
- Record id
cardio:ct-nct05243199- Content hash
4d05d61a26db011652db2f3a68ca1761aa9b8ebbc7987318acaa39ffbfdaf0cf